These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1116 related articles for article (PubMed ID: 14555524)

  • 21. Regulation of prostate-specific antigen gene expression by an LH-RH analogue in human prostatic cells.
    Sica G; Zelano G; Settesoldi D; Iacopino F
    Anticancer Res; 2003; 23(2B):1283-7. PubMed ID: 12820384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
    Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
    Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.
    Gnanapragasam VJ; Darby S; Khan MM; Lock WG; Robson CN; Leung HY
    J Pathol; 2005 Jun; 206(2):205-13. PubMed ID: 15818594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor.
    Föst C; Duwe F; Hellriegel M; Schweyer S; Emons G; Gründker C
    Oncol Rep; 2011 May; 25(5):1481-7. PubMed ID: 21331448
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone.
    Miyazaki M; Nagy A; Schally AV; Lamharzi N; Halmos G; Szepeshazi K; Groot K; Armatis P
    J Natl Cancer Inst; 1997 Dec; 89(23):1803-9. PubMed ID: 9392622
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective treatment of experimental androgen sensitive and androgen independent intraosseous prostate cancer with targeted cytotoxic somatostatin analogue AN-238.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    J Urol; 2004 Feb; 171(2 Pt 1):911-5. PubMed ID: 14713852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice.
    Koppán M; Nagy A; Schally AV; Plonowski A; Halmos G; Arencibia JM; Groot K
    Prostate; 1999 Feb; 38(2):151-8. PubMed ID: 9973101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.
    Engel J; Emons G; Pinski J; Schally AV
    Expert Opin Investig Drugs; 2012 Jun; 21(6):891-9. PubMed ID: 22577891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of in vivo proliferation of MDA-PCa-2b human prostate cancer by a targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
    Plonowski A; Schally AV; Nagy A; Groot K; Krupa M; Navone NM; Logothetis C
    Cancer Lett; 2002 Feb; 176(1):57-63. PubMed ID: 11790454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer.
    Bhattacharyya RS; Husbeck B; Feldman D; Knox SJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):935-40. PubMed ID: 18760546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
    Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
    Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers.
    Letsch M; Schally AV; Stangelberger A; Groot K; Varga JL
    Eur J Cancer; 2004 Feb; 40(3):436-44. PubMed ID: 14746863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells.
    Tso CL; McBride WH; Sun J; Patel B; Tsui KH; Paik SH; Gitlitz B; Caliliw R; van Ophoven A; Wu L; deKernion J; Belldegrun A
    Cancer J; 2000; 6(4):220-33. PubMed ID: 11038142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) anlalogs inhibit growth of estrogen independent MXT mouse mammary cancers in vivo by decreasing cell proliferation and inducing apoptosis.
    Szepeshazi K; Schally AV; Nagy A; Halmos G; Groot K
    Anticancer Drugs; 1997 Nov; 8(10):974-87. PubMed ID: 9436641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.
    Berenguer C; Boudouresque F; Dussert C; Daniel L; Muracciole X; Grino M; Rossi D; Mabrouk K; Figarella-Branger D; Martin PM; Ouafik L
    Oncogene; 2008 Jan; 27(4):506-18. PubMed ID: 17637748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bombesin and epidermal growth factor potentiate the effect of cytotoxic LH-RH analog AN-152 in vitro.
    Krebs LJ; Wang X; Nagy A; Schally AV; Prasad PN; Liebow C
    Int J Oncol; 2002 Dec; 21(6):1325-9. PubMed ID: 12429984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.